PLASMA Act

This bill changes how much drug companies must discount certain medicines made from blood plasma for Medicare patients. Currently, drug companies must give a 10% discount during one phase of coverage and a 20% discount during another phase. The bill allows companies that make plasma-derived products to start with much smaller discounts in 2026 and slowly increase them over several years. By 2030, these companies would give the same 10% discount as other drug companies, and by 2032, they would give the full 20% discount.

Your Vote